Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q3 FY23 results · Oct–Dec 2022

Jubilant Pharmova reported revenue from operations of ₹1,552.51 crore (up 18.5% from Q3 FY22) and net loss of ₹16.04 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	1,552.51	1,310.53	+18.5%	1,599.50	−2.9%
Other income	9.47	5.91	+60.2%	13.10	−27.7%
Total income	1,561.98	1,316.44	+18.7%	1,612.60	−3.1%
Profit before share of associates & JVs and tax	10.38	70.20	−85.2%	39.06	−73.4%
Share of profit/(loss) of associates & JVs	(1.65)	0.03		(2.66)
Net profit for the period	(16.04)	50.80	Turned loss	4.92	Turned loss
Attributable to shareholders of the company	(15.67)	50.99	Turned loss	5.49	Turned loss
EPS, basic (₹)	(0.98)	3.20	Turned loss	0.34	Turned loss
Net margin (%)	-1.0	3.9		0.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	182.74	18.67	+878.8%	222.97	−18.0%
Other income	7.87	8.58	−8.3%	106.12	−92.6%
Total income	190.61	27.25	+599.5%	329.09	−42.1%
Profit before tax	(11.14)	(6.22)	Loss widened	98.20	Turned loss
Net profit for the period	(5.89)	(5.34)	Loss widened	91.81	Turned loss
EPS, basic (₹)	(0.37)	(0.34)	Loss widened	5.77	Turned loss
Net margin (%)	-3.2	-28.6		41.2

Consolidated

Filed with BSE: 06 Feb 2023, 17:27 IST
Board meeting: 03 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 06 Feb 2023, 17:27 IST
Board meeting: 03 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE